Today was the fallout of the AMGN bid for ONXX. There are a couple of aspects of it that I want to touch on and go a little further than.
Not much of a lot of new today but there were some interesting tidbits. 1. BIIB spiked higher today on the back of SNY news. The EMA granted Aubagio exclusivity.
Generally it was a good bounce back day for a lot of biotechs, although there were some pockets of underperformance. That being said, this is a positive day but the.
There was a lot that happened last week that I will slowly get to go through it the next week but on a big picture macro front, I actually think.
Was a quiet day on the news front, so I will keep this short(er). I am just getting a sneaking suspicion that we are heading into another period where macro.
It was an odd day in the market with weakness early followed but a rally in the afternoon that made it look like we would get to unchanged (or even.
[This was meant to be posted Friday afternoon but did not seem to go through, so you get a bonus EOD of today] I do not think there is not.
Rough day in the market today and biotechs were clearly not immune. Aside from the general downtrend there were some stock specific stories. 1. There was some strategic restructuring at.
Happy mid-ASCO (although most of the data is already presented). Some interesting ASCO and, surprisingly, non-ASCO stories. 1. I added to my SGEN position today (at $33.67). It has been.
A bit of a quite day today in the markets. There is some biotech news but it seems to be the calm before the storm of ASCO, or as I.